BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 15273729)

  • 21. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
    Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
    J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation.
    Rosini P; Bonaccorsi L; Baldi E; Chiasserini C; Forti G; De Chiara G; Lucibello M; Mongiat M; Iozzo RV; Garaci E; Cozzolino F; Torcia MG
    Prostate; 2002 Dec; 53(4):310-21. PubMed ID: 12430142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of vascular endothelial growth factor induces cell transformation in cooperation with fibroblast growth factor 2.
    Guerrin M; Scotet E; Malecaze F; Houssaint E; Plöuet J
    Oncogene; 1997 Jan; 14(4):463-71. PubMed ID: 9053843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Responses of vascular endothelial cells to angiogenic signaling are important for tumor cell survival.
    Shan S; Robson ND; Cao Y; Qiao T; Li CY; Kontos CD; Garcia-Blanco M; Dewhirst MW
    FASEB J; 2004 Feb; 18(2):326-8. PubMed ID: 14688196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
    Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
    Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer.
    Giri D; Ropiquet F; Ittmann M
    Clin Cancer Res; 1999 May; 5(5):1063-71. PubMed ID: 10353739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential mechanisms regulating the extracellular activities of basic fibroblast growth factor (FGF-2).
    Baird A
    Mol Reprod Dev; 1994 Sep; 39(1):43-8. PubMed ID: 7528026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC; Scicli GM; McMahon G; Scicli AG
    Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibroblast growth factor-2 mediates Angiotensin-converting enzyme inhibitor-induced angiogenesis in coronary endothelium.
    Donnini S; Solito R; Giachetti A; Granger HJ; Ziche M; Morbidelli L
    J Pharmacol Exp Ther; 2006 Nov; 319(2):515-22. PubMed ID: 16868034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Modulation of the tumoral progression by anti-idiotypic antibodies of angiogenesis factors].
    Ortéga N; Jonca F; Vincent S; Favard C; Malavaud B; Bertrand N; Mazerolles C; Richmann P; Pouliquen Y; Sarrammon JP; Ruchoux MM; Plouët J
    C R Acad Sci III; 1996 May; 319(5):411-5. PubMed ID: 8763741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression and potential role of fibroblast growth factor 2 and its receptors in human embryonic stem cells.
    Dvorak P; Dvorakova D; Koskova S; Vodinska M; Najvirtova M; Krekac D; Hampl A
    Stem Cells; 2005 Sep; 23(8):1200-11. PubMed ID: 15955829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of a transfected FGFR-1 receptor in Madin-Darby epithelial cells results in a reversible loss of epithelial properties.
    Migdal M; Soker S; Yarden Y; Neufeld G
    J Cell Physiol; 1995 Feb; 162(2):266-76. PubMed ID: 7529769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Localisation and differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal and atherosclerotic human arteries.
    Hughes SE
    Cardiovasc Res; 1996 Sep; 32(3):557-69. PubMed ID: 8881516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
    Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parathyroid hormone regulates the expression of fibroblast growth factor-2 mRNA and fibroblast growth factor receptor mRNA in osteoblastic cells.
    Hurley MM; Tetradis S; Huang YF; Hock J; Kream BE; Raisz LG; Sabbieti MG
    J Bone Miner Res; 1999 May; 14(5):776-83. PubMed ID: 10320526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostaglandin E(2) primes the angiogenic switch via a synergic interaction with the fibroblast growth factor-2 pathway.
    Finetti F; Donnini S; Giachetti A; Morbidelli L; Ziche M
    Circ Res; 2009 Sep; 105(7):657-66. PubMed ID: 19713533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
    Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
    Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly.
    Ibrahimi OA; Zhang F; Hrstka SC; Mohammadi M; Linhardt RJ
    Biochemistry; 2004 Apr; 43(16):4724-30. PubMed ID: 15096041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.